ERNA
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
Ernexa Therapeutics Inc. (ERNA) is rated C- (1.9/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Profitability (F). The rating has held at C- for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | B+ (3.7) | D+ (1.8) | F (0.6) | D- (0.8) | C+ (2.6) | C- (1.9) |
| 2026-11-04 | B+ (3.7) | C- (1.9) | F (0.7) | D (1.2) | C+ (2.7) | C- (2.0) |
| 2026-10-28 | B+ (3.7) | C- (1.9) | F (0.7) | D (1.3) | C+ (2.7) | C- (2.0) |
| 2026-10-21 | B+ (3.7) | D+ (1.8) | F (0.6) | D (1.3) | C+ (2.6) | C- (2.0) |
| 2026-10-14 | B+ (3.7) | D+ (1.8) | F (0.6) | D- (1.1) | C+ (2.6) | C- (2.0) |